Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cassava Sciences Inc
(NQ:
SAVA
)
29.41
+0.30 (+1.03%)
Streaming Delayed Price
Updated: 11:47 AM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
19
20
Next >
Nasdaq Jumps Over 300 Points; Boeing Posts Wider-Than-Expected Loss
July 27, 2022
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 300 points on Wednesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
July 27, 2022
Wednesday saw 83 companies set new 52-week lows.
Via
Benzinga
Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe
July 27, 2022
SAVA stock is tumbling 30% in pre-market trading on a report that the Justice Department had launched a criminal probe of the company.
Via
InvestorPlace
Cassava Sciences Shares Plunge After Criminal Investigation Report
July 27, 2022
Via
Benzinga
Recap: Cassava Sciences Q1 Earnings
May 05, 2022
Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
This Asset Management Stock Is Trading Higher By More Than 45%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
July 27, 2022
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 67.8% to $3.4390. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital...
Via
Benzinga
GOOG Stock Pops as Alphabet Earnings Report Shows Strong Ad Revenue
July 27, 2022
Alphabet (GOOG,GOOGL) stock is on the rise Wednesday as investors react to the tech giant's earnings report for the second quarter of 2022.
Via
InvestorPlace
Cassava Sciences May Be Heading Below $10 Per Share
May 04, 2022
Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall.
Via
InvestorPlace
Spotify (SPOT) Stock Gains on Impressive User Growth
July 27, 2022
Spotify (SPOT) stock is on the rise Wednesday as investors react to a strong earnings report for the second quarter of 2022.
Via
InvestorPlace
Why U.S. Stocks Are Trading Higher Ahead Of Fed Decision; Alphabet Earnings Miss Views
July 27, 2022
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 250 points on Wednesday.
Via
Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
July 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 27, 2022
Via
Benzinga
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27
July 27, 2022
Reuters Monkeypox Emergency Could Last Months, According To Experts
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 27, 2022
Good morning, investor! Wednesday starts with a breakdown of the biggest pre-market stock movers for traders to keep an eye on!
Via
InvestorPlace
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session
July 27, 2022
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022.
Via
Benzinga
7 Meme Stocks Trading at a Massive Discount Right Now
July 24, 2022
'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now.
Via
InvestorPlace
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
July 20, 2022
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050.
Via
Benzinga
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
June 15, 2022
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.
Via
Benzinga
5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise
June 06, 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 31, 2022
Via
Benzinga
The 7 Best Meme Stocks to Buy Now
May 25, 2022
The meme stock craze might never be what it was last year, but these meme stocks to buy that are still worth another look.
Via
InvestorPlace
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
May 24, 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Via
Benzinga
Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop
May 23, 2022
Short squeeze stocks continue to be of interest to retail traders looking to pump up shares while pushing hedge funds out of a company.
Via
InvestorPlace
How Is The Market Feeling About Cassava Sciences?
May 12, 2022
Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has 11.46 million shares sold short, which is...
Via
Benzinga
What Are Whales Doing With Cassava Sciences
May 04, 2022
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
May 03, 2022
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market...
Via
Benzinga
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
April 29, 2022
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point.
Via
InvestorPlace
Take Full Advantage of Weakness in Cassava Sciences Stock
April 26, 2022
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again.
Via
InvestorPlace
Cassava Sciences Is a Worthwhile Bet to Consider
April 25, 2022
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up.
Via
InvestorPlace
The Crowd Has Wisely Soured on Cassava Sciences Stock
April 20, 2022
Recent headlines suggest Simulfilam has a slim chance of obtaining FDA approval, justifying the move of SAVA stock to lower prices.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.